Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions

Targeting CDK pathways in cancer treatment

DNA repair inhibitors to overcome drug resistance

Refining the role of PARP inhibitors in targeted anticancer therapy

Developments in immunotherapy

Putting adoptive T cell therapy on the path to regulatory approval

Using Hsp90 inhibitors in the clinic: what have we learned?

Radiogenomic evaluation of tumour response to targeted agents

Mutant-specific kinase inhibitors and TAT highlights

New drugs and targets in haematological malignancies

Drugging the cancer genome to overcome drug resistance

ecancermedicalscience editor's choice for February 2015